Angiopoietin-like 3 in lipoprotein metabolism

Kersten, Sander

doi:10.1038/nrendo.2017.119

Cited by 221Lipid metabolism and disordersLipoproteins and Cardiovascular HealthLipid metabolism and biosynthesis

Angiopoietin-like 3 in lipoprotein metabolism

Open access

Kersten, Sander·2017·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2017.119

Open this paper in CoChat — free account

Abstract

Triglycerides and cholesterol circulate in the bloodstream as part of various lipoprotein particles. Three members of the angiopoietin-like (ANGPTL) protein family - ANGPTL3, ANGPTL4 and ANGPTL8 - have emerged as important regulators of plasma lipoprotein levels by inhibiting the enzyme lipoprotein lipase. Here, I review the role of ANGPTL3 in lipoprotein metabolism. In contrast to ANGPTL4 and ANGPTL8, ANGPTL3 is exclusively produced in the liver and can therefore be classified as a true hepatokine. ANGPTL3 cooperates with ANGPTL8 to inhibit lipoprotein lipase and is mostly active after feeding, whereas ANGPTL4 is mostly active after fasting. Inactivation of ANGPTL3 in mice reduces plasma triglyceride and free fatty acid levels and suppresses atherosclerosis. In humans, homozygous loss-of-function mutations in ANGPTL3 lead to low plasma levels of low-density lipoproteins, high-density lipoproteins and triglycerides, a condition referred to as familial combined hypolipidaemia. Heterozygous carriers of loss-of-function mutations in ANGPTL3 have a lower risk of coronary artery disease than non-carriers. At present, researchers are investigating antisense oligonucleotide and monoclonal antibody-based inactivation of ANGPTL3 in human clinical trials for the therapeutic management of dyslipidaemia and atherosclerosis. Thus, ANGPTL3 is an important liver-derived regulator of lipoprotein metabolism that holds considerable promise as a target for atherosclerosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrendo.2017.119

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ANGPTL3 codes for a glycoprotein with roles in angiogenesis, tissue remodeling, inflammation, and inhibition of lipoprotein lipase (LPL) catalytic activity.
“which codes for a glycoprotein with roles in angiogenesis, tissue remodeling, inflammation, and inhibition of lipoprotein lipase (LPL) catalytic activity [93–95]”
From Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits (2021) · cites this paper as [95]
The available passages contain the paper’s title and bibliographic metadata, but no substantive text about ANGPTL3’s functions. Searches for angiogenesis, tissue remodeling, inflammation, and inhibition of lipoprotein lipase returned no passage that verifies the claim. (LLM, conf=0.72)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2 retracted

RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation
Yi, P., Park, J.-S., & Melton, D. A. (2013) · Cell · doi:10.1016/j.cell.2013.04.008 · Cited by 449 · see citing works
Retracted
Retraction Notice to: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation
Peng, Y., Park, J.-S., & Melton, D. A. (2016) · Cell · doi:10.1016/j.cell.2016.12.017 · Cited by 49 · see citing works
Retracted
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · see citing works
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585 · see citing works
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386 · see citing works
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885 · see citing works
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · see citing works
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573 · see citing works
Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene
Kersten, S., Mandard, S., Tan, N. S., Escher, P., METZGER, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 560 · see citing works
Self-citation
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 548 · see citing works
Self-citation
ANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467 · see citing works
Atypical angiopoietin-like protein that regulates ANGPTL3
Quagliarini, F., Wang, Y., Kozlitina, J., Grishin, N. V., Hyde, R., Boerwinkle, E., Valenzuela, D. M., Murphy, A. J., Cohen, J. C., & Hobbs, H. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217552109 · Cited by 451 · see citing works
Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism
Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427 · see citing works
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans
Romeo, S., Wu, Y., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 422 · see citing works
Angptl3 regulates lipid metabolism in mice
Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H., & Furukawa, H. (2002) · Nature Genetics · doi:10.1038/ng814 · Cited by 420 · see citing works
Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue
Sukonina, V., Lõokene, A., Olivecrona, T., & Olivecrona, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604026103 · Cited by 402 · see citing works
ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase
Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 370 · see citing works
Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells
Zhang, C. C., Kaba, M., Ge, G., Xie, K. T., Tong, W., Hug, C., & Lodish, H. F. (2006) · Nature Medicine · doi:10.1038/nm1342 · Cited by 367 · see citing works
Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels
Zhang, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.038 · Cited by 345 · see citing works
Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis
Wang, Y., Quagliarini, F., Gusarova, V., Gromada, J., Valenzuela, D. M., Cohen, J. C., & Hobbs, H. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315292110 · Cited by 317 · see citing works
Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism
Ren, G., Kim, J. Y., & Smas, C. M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00084.2012 · Cited by 299 · see citing works
Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase
Shimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297 · see citing works
Angptl4 Protects against Severe Proinflammatory Effects of Saturated Fat by Inhibiting Fatty Acid Uptake into Mesenteric Lymph Node Macrophages
Lichtenstein, L., Mattijssen, F., de Wit, N. J. W., Georgiadi, A., Hooiveld, G. J. E. J., van der Meer, R., He, Y., Qi, L., Koster, A. M., Tamsma, J. T., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.002 · Cited by 269 · see citing works
Self-citation
ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo
Camenisch, G., Pisabarro, M. T., Sherman, D. A., Kowalski, J., Nagel, M., Hass, P., Xie, M.-H., Gurney, A. L., Bodary, S. C., Liang, X. H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109768200 · Cited by 253 · see citing works
ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210 · see citing works
Protein Region Important for Regulation of Lipid Metabolism in Angiopoietin-like 3 (ANGPTL3)
Ono, M., Shimizugawa, T., Shimamura, M., Yoshida, K., Noji-Sakikawa, C., Ando, Y., Koishi, R., & Furukawa, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302861200 · Cited by 207 · see citing works
ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion
Gusarova, V., Alexa, C. A., Na, E., Stevis, P. E., Xin, Y., Bonner-Weir, S., Cohen, J. C., Hobbs, H. H., Murphy, A. J., Yancopoulos, G. D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.027 · Cited by 202 · see citing works
ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance
Haller, J. F., Mintah, I. J., Shihanian, L. M., Stevis, P. E., Buckler, D., Alexa-Braun, C. A., Kleiner, S., Banfi, S., Cohen, J. C., Hobbs, H. H., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075689 · Cited by 201 · see citing works
Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice
Desai, U. S., Lee, E.-C., Chung, K., Gao, C., Gay, J. P., Key, B., Hansen, G. M., Machajewski, D., Platt, K. A., Sands, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705041104 · Cited by 192 · see citing works
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189 · see citing works
Regulation of triglyceride metabolism by Angiopoietin-like proteins
Mattijssen, F., & Kersten, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.010 · Cited by 180 · see citing works
Self-citation
Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids
Robciuc, M. R., Maranghi, M., Lahikainen, A., Rader, D. J., Bensadoun, A., Öörni, K., Metso, J., Minicocci, I., Ciociola, E., Ceci, F., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301397 · Cited by 176 · see citing works
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Chi, X., Britt, E. C., Shows, H. W., Hjelmaas, A. J., Shetty, S. K., Cushing, E. M., Li, W. S., Dou, A., Zhang, R., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.014 · Cited by 175 · see citing works
Identification of a mammalian angiopoietin-related protein expressed specifically in liver
Conklin, D., Gilbertson, D., Taft, D. W., Maurer, M. F., Whitmore, T. E., Smith, D. L., Walker, K. M., Chen, L. H., Wattler, S., Nehls, M., et al. (1999) · Genomics · doi:10.1006/geno.1999.6041 · Cited by 169 · see citing works
Mutations in the ANGPTL3 Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization
Minicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V., Labbadia, G., Gabiati, C., Pigna, G., Sepe, M. L., Pannozzo, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1298 · Cited by 168 · see citing works
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23]
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162 · see citing works
Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)
Lee, E.-C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X., Gay, J. P., Wilganowski, N., Gao, C., Du, L.-L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807899200 · Cited by 161 · see citing works
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159 · see citing works
Differential regulation and properties of angiopoietin-like proteins 3 and 4
Ge, H., Cha, J.-Y., Gopal, H., Harp, C. T., Yu, X., Repa, J. J., & Li, C. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500005-jlr200 · Cited by 153 · see citing works
Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise
Catoire, M., Alex, S., Paraskevopulos, N., Mattijssen, F., Evers-van Gogh, I., Schaart, G., Jeppesen, J., Kneppers, A., Mensink, M., Voshol, P. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400889111 · Cited by 150 · see citing works
Self-citation
Angiopoietin-like Protein 3 Mediates Hypertriglyceridemia Induced by the Liver X Receptor
Inaba, T., Matsuda, M., Shimamura, M., Takei, N., Terasaka, N., Ando, Y., Yasumo, H., Koishi, R., Makishima, M., & Shimomura, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213202200 · Cited by 138 · see citing works
The Angiopoietin-like Proteins ANGPTL3 and ANGPTL4 Inhibit Lipoprotein Lipase Activity through Distinct Mechanisms
Shan, L., Yu, X., Liu, Z., Hu, Y., Sturgis, L., Miranda, M. L., & Liu, Q. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808477200 · Cited by 137 · see citing works
Hepatic ANGPTL3 regulates adipose tissue energy homeostasis
Wang, Y., McNutt, M., Banfi, S., Levin, M. G., Holland, W. L., Gusarova, V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515374112 · Cited by 136 · see citing works
O-Glycosylation Modulates Proprotein Convertase Activation of Angiopoietin-like Protein 3
Schjoldager, K. T.-B. G., Vester-Christensen, M. B., Bennett, E., Levery, S. B., Schwientek, T., Yin, W., Blixt, O., & Clausen, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.156950 · Cited by 135 · see citing works
Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family
Fu, Z., Yao, F., Abou‐Samra, A., & Zhang, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.025 · Cited by 134 · see citing works
Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents
Khetarpal, S. A., Schjoldager, K. T.-B. G., Christoffersen, C., Raghavan, A., Edmondson, A. C., Reutter, H. M., Bouhouche, A., Ouazzani, R., Peloso, G. M., Vitali, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.012 · Cited by 131 · see citing works
ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure
Dijk, W., Heine, M., Vergnes, L., Boon, M. R., Schaart, G., Hesselink, M. K. C., Reue, K., Lichtenbelt, W. D. V. M., Olivecrona, G., Rensen, P. C. N., et al. (2015) · eLife · doi:10.7554/elife.08428 · Cited by 130 · see citing works
Self-citation
Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3
Pisciotta, L., Favari, E., Magnolo, L., Simonelli, S., Adorni, M. P., Sallo, R., Fancello, T., Zavaroni, I., Ardigò, D., Bernini, F., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960674 · Cited by 128 · see citing works
Regulation of the angiopoietin-like protein 3 gene by LXR
Kaplan, R. A., Zhang, T., Hernandez, M., Gan, F. X., Wright, S. D., Waters, M. G., & Cai, T. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200367-jlr200 · Cited by 127 · see citing works
Hepatic Proprotein Convertases Modulate HDL Metabolism
Jin, W., Wang, X., Millar, J. S., Quertermous, T., Rothblat, G. H., Glick, J. M., & Rader, D. J. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.009 · Cited by 126 · see citing works
Angiopoietin-like Protein 3 Inhibits Lipoprotein Lipase Activity through Enhancing Its Cleavage by Proprotein Convertases
Liu, J., Huq, A., Rader, D. J., & Jin, W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.144279 · Cited by 124 · see citing works
GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4
Sonnenburg, W. K., Yu, D., Lee, E.-C., Xiong, W., Gololobov, G., Key, B., Gay, J. P., Wilganowski, N., Hu, Y., Zhao, S., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900145-jlr200 · Cited by 123 · see citing works
The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding
Mysling, S., Kristensen, K. K., Larsson, M., Kovrov, O., Bensadoun, A., Jørgensen, T. J. D., Olivecrona, G., Young, S. G., & Ploug, M. (2016) · eLife · doi:10.7554/elife.20958 · Cited by 121 · see citing works
Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes
Dijk, W., Beigneux, A. P., Larsson, M., Bensadoun, A., Young, S. G., & Kersten, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m067363 · Cited by 119 · see citing works
Self-citation
A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme Dimerization
Yau, M.-H., Wang, Y., Lam, K. S. L., Zhang, J., Wu, D., & Xu, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809802200 · Cited by 118 · see citing works
Elevated Mouse Hepatic Betatrophin Expression Does Not Increase Human β-Cell Replication in the Transplant Setting
Jiao, Y., Le Lay, J., Yu, M., Naji, A., & Kaestner, K. H. (2014) · Diabetes · doi:10.2337/db13-1435 · Cited by 118 · see citing works
The acute phase response stimulates the expression of angiopoietin like protein 4
Lü, B., Moser, A. H., Shigenaga, J. K., Grünfeld, C., & Feingold, K. R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.145 · Cited by 116 · see citing works
Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes
Shimamura, M., Matsuda, M., Kobayashi, S., Ando, Y., Ono, M., Koishi, R., Furukawa, H., Makishima, M., & Shimomura, I. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03058-9 · Cited by 112 · see citing works
Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample
Robciuc, M. R., Tahvanainen, E., Jauhiainen, M., & Ehnholm, C. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m002618 · Cited by 107 · see citing works
Angptl3-null Mice Show Low Plasma Lipid Concentrations by Enhanced Lipoprotein Lipase Activity
FUJIMOTO, K., KOISHI, R., SHIMIZUGAWA, T., & ANDO, Y. (2006) · Experimental Animals · doi:10.1538/expanim.55.27 · Cited by 104 · see citing works
A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice
Ando, Y., Shimizugawa, T., Takeshita, S., Ono, M., Shimamura, M., Koishi, R., & Furukawa, H. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300031-jlr200 · Cited by 101 · see citing works
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
Orringer, C. E., Jacobson, T. A., Saseen, J. J., Brown, A. S., Gotto, A. M., Ross, J. L., & Underberg, J. A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.001 · Cited by 101 · see citing works
Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p039875 · Cited by 97 · see citing works
Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin
Haridas, P. A. N., Soronen, J., Sädevirta, S., Mysore, R., Quagliarini, F., Pasternack, A. H., Metso, J., Perttilä, J., Leivonen, M., Smas, C. M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1254 · Cited by 83 · see citing works
ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states
Inukai, K., Nakashima, Y., Watanabe, M., Kurihara, S., Awata, T., Katagiri, H., Oka, Y., & Katayama, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.151 · Cited by 82 · see citing works
Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia
Noto, D., Cefalu, A. B., Valenti, V., Fayer, F., Pinotti, E., Ditta, M., Spina, R., Vigna, G. B., Yue, P., Kathiresan, S., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238766 · Cited by 82 · see citing works
Linking nutritional regulation of Angptl4, Gpihbp1, and Lmf1 to lipoprotein lipase activity in rodent adipose tissue
Kroupa, O., Vorrsjö, E., Stienstra, R., Mattijssen, F., Nilsson, S. K., Sukonina, V., Kersten, S., Olivecrona, G., & Olivecrona, T. (2012) · BMC Physiology · doi:10.1186/1472-6793-12-13 · Cited by 82 · see citing works
Self-citation
Differential Association of Plasma Angiopoietin-Like Proteins 3 and 4 With Lipid and Metabolic Traits
Mehta, N., Qamar, A., Qu, L., Qasim, A., Mehta, N. N., Reilly, M. P., & Rader, D. J. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302802 · Cited by 80 · see citing works
The Lipoprotein Lipase Inhibitor ANGPTL3 Is Negatively Regulated by Thyroid Hormone
Fugier, C., Tousaint, J.-J., Prieur, X., Plateroti, M., Samarut, J., & Delerive, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512554200 · Cited by 74 · see citing works
Angiopoietin-like protein 8 (ANGPTL8)/betatrophin overexpression does not increase beta cell proliferation in mice
Cox, A. R., Lam, C. J., Bonnyman, C. W., Chavez, J., Rios, J. S., & Kushner, J. A. (2015) · Diabetologia · doi:10.1007/s00125-015-3590-z · Cited by 66 · see citing works
Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation
Martín-Campos, J. M., Roig, R., Mayoral, C., Martinez, S., Martí, G., Arroyo, J. A., Julve, J., & Blanco‐Vaca, F. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.11.020 · Cited by 65 · see citing works
Furin Is the Primary in Vivo Convertase of Angiopoietin-like 3 and Endothelial Lipase in Hepatocytes
Essalmani, R., Susan‐Resiga, D., Chamberland, A., Asselin, M.-C., Canuel, M., Constam, D. B., Creemers, J. W. M., Day, R. W., Gauthier, D., Prat, A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.501304 · Cited by 62 · see citing works
Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXR
Matsusue, K., Miyoshi, A., Yamano, S., & Gonzalez, F. J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.05.005 · Cited by 60 · see citing works
Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
Minicocci, I., Tikka, A., Poggiogalle, E., Metso, J., Montali, A., Ceci, F., Labbadia, G., Fontana, M., Di Costanzo, A., Maranghi, M., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066183 · Cited by 56 · see citing works
A novel role of angiopoietin-like-3 associated with podocyte injury
Liu, J., Gao, X., Zhai, Y., Shen, Q., Sun, L., Feng, C., Rao, J., Liu, H., Zha, X., Guo, M., et al. (2015) · Pediatric Research · doi:10.1038/pr.2015.38 · Cited by 43 · see citing works
Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism
Pramfalk, C., Parini, P., Gustafsson, U. O., Sahlin, S., & Eriksson, M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02305.x · Cited by 40 · see citing works
Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation
Tikka, A., Soronen, J., Laurila, P., Metso, J., Ehnholm, C., & Jauhiainen, M. (2014) · Bioscience Reports · doi:10.1042/bsr20140115 · Cited by 39 · see citing works
A form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene
Fazio, S., Sidoli, A., Vivenzio, A., Maietta, A., Giampaoli, S., Menotti, A., Antonini, R., Urbinati, G., Baralle, F. E., & RICCI, G. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00304.x · Cited by 37 · see citing works
Fasting-induced adipose factor/angiopoietin–like protein 4: a potential target for dyslipidemia?
Zandbergen, F. J., van Dijk, S. J., Müller, M. M., & Kersten, S. (2006) · Future Lipidology · doi:10.2217/17460875.1.2.227 · Cited by 33 · see citing works
Self-citation
Novel Approaches for the Treatment of Familial Hypercholesterolemia
Bonanni, L., Cutolo, A., & Vestra, M. D. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-109063 · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F., Xie, C., & Jiang, C.-T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 376 · see citing works
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315 · see citing works
Evinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302 · see citing works
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279 · see citing works
Causes and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239 · see citing works
Lipoprotein lipase and its regulators: an unfolding story
Wu, S. A., Kersten, S., & Qi, L. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.11.005 · Cited by 225 · see citing works
Self-citation
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
Carbone, C., Piro, G., Merz, V., Simionato, F., Santoro, R., Zecchetto, C., Tortora, G., & Melisi, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020431 · Cited by 217 · see citing works
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404147 · Cited by 213 · see citing works
ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue
Iizuka, K., Takao, K., & Yabe, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.587189 · Cited by 152 · see citing works
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140 · see citing works
Mouse models of atherosclerosis in translational research
Ilyas, I., Little, P. J., Liu, Z., Xu, Y., Kamato, D., Berk, B. C., Weng, J., & Xu, S. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.06.009 · Cited by 115 · see citing works
Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis
Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa972 · Cited by 89 · see citing works
Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease
Cadby, G., Giles, C., Melton, P. E., Huynh, K., Mellett, N. A., Duong, T., Nguyen, T. A., Cinel, M. A., Smith, A., Olshansky, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30875-7 · Cited by 104 · see citing works
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 110 · see citing works
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., Clifton, P., Hamilton, J., Given, B., Melquist, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02494-2 · Cited by 105 · see citing works
The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation
Abu‐Farha, M., Ghosh, A., Al‐Khairi, I., Madiraju, S. R. M., Abubaker, J. A., & Prentki, M. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101067 · Cited by 94 · see citing works
Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Chen, P., Gao, W.-Y., Liou, J.-W., Lin, C.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147310 · Cited by 80 · see citing works
Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism
Kristensen, K. K., Leth-Espensen, K. Z., Mertens, H. D. T., Birrane, G., Muthuraman, M., Olivecrona, G., Jørgensen, T. J. D., Young, S. G., & Ploug, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920202117 · Cited by 77 · see citing works
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 68 · see citing works
Dietary Flavonoids as Modulators of Lipid Metabolism in Poultry
Tan, Z., Halter, B., Liu, D., Gilbert, E. R., & Cline, M. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.863860 · Cited by 67 · see citing works
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T. D., Dimitriou, T., & Elisaf, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541348 · Cited by 66 · see citing works
A long hypoxia-inducible factor 3 isoform 2 is a transcription activator that regulates erythropoietin
Tolonen, J.-P., Heikkilä, M., Malinen, M., Lee, H.-M., Palvimo, J. J., Wei, G.-H., & Myllyharju, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03387-9 · Cited by 63 · see citing works
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 62 · see citing works
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets
Katz, L. S., Baumel-Alterzon, S., Scott, D. K., & Herman, M. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100623 · Cited by 59 · see citing works
Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver–Adipose Tissue Crosstalk
Morán-Costoya, A., Proenza, A. M., Gianotti, M., Lladó, I., & Valle, A. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0044 · Cited by 58 · see citing works
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58 · see citing works
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
Luo, F., Das, A., Khetarpal, S. A., Fang, Z., Zelniker, T. A., Rosenson, R. S., & Qamar, A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.008 · Cited by 58 · see citing works
Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease
Biterova, E. I., Esmaeeli, M., Alanen, H. I., Saaranen, M. J., & Ruddock, L. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-25237-7 · Cited by 57 · see citing works
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54 · see citing works
Self-citation
Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial.
Wang, J., Zhao, J., Yan, C., Xi, C., Wu, C., Zhao, J.-X., Li, F.-W., Ding, Y.-H., Zhang, R., Qi, S., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.03.006 · Cited by 43 · see citing works
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52 · see citing works
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01071-1 · Cited by 48 · see citing works
Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
Kim, T. H., Hong, D.-G., & Yang, Y. M. (2021) · Biomedicines · doi:10.3390/biomedicines9121903 · Cited by 52 · see citing works
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 47 · see citing works
New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases
Su, X., & Peng, D. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0659-y · Cited by 45 · see citing works
Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome
Chaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 46 · see citing works
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 44 · see citing works
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 43 · see citing works
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 43 · see citing works
Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
Tikkanen, E., Minicocci, I., Hällfors, J., Costanzo, A. D., D’Erasmo, L., Poggiogalle, E., Donini, L. M., Würtz, P., Jauhiainen, M., Olkkonen, V. M., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312021 · Cited by 41 · see citing works
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency
Arca, M., D’Erasmo, L., & Minicocci, I. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000668 · Cited by 41 · see citing works
New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Olkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 41 · see citing works
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 37 · see citing works
Relationship between hepatic and systemic angiopoietin‐like 3, hepatic Vitamin D receptor expression and NAFLD in obesity
Barchetta, I., Cimini, F. A., Chiappetta, C., Bertoccini, L., Ceccarelli, V., Capoccia, D., Gaggini, M., Cristofano, C. D., Rocca, C. D., Silecchia, G., et al. (2020) · Liver International · doi:10.1111/liv.14554 · Cited by 37 · see citing works
Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes
Latorre, J., Ortega, F. J., Liñares‐Pose, L., Moreno‐Navarrete, J. M., Lluch, A., Comas, F., Oliveras‐Cañellas, N., Ricart, W., Höring, M., Zhou, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102697 · Cited by 35 · see citing works
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34 · see citing works
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 35 · see citing works
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33 · see citing works
Emerging roles of angiopoietin‐like proteins in inflammation: Mechanisms and potential as pharmacological targets
Yang, J. X., Song, Q., Niu, S., Chen, H., Petersen, R. B., Zhang, Y., & Huang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30534 · Cited by 32 · see citing works
GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 32 · see citing works
Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia
Paragh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 34 · see citing works
Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 37 · see citing works
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 35 · see citing works
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
Foss‐Freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01589-4 · Cited by 30 · see citing works
Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
Stefanutti, C., Chan, D. C., Giacomo, S. D., Morozzi, C., & Watts, G. F. (2022) · Pharmaceuticals · doi:10.3390/ph15111389 · Cited by 30 · see citing works
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 30 · see citing works
Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism
Yang, L., Yin, R., Wang, Z., Wang, X., Zhang, Y., & Zhao, D. (2019) · BioMed Research International · doi:10.1155/2019/3814687 · Cited by 27 · see citing works
Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits
Tierney, E., Remaley, A. T., Thurm, A., Jager, L. R., Wassif, C. A., Kratz, L. E., Bailey-Wilson, J. E., Bukelis, I., Sarphare, G., Jung, E. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01580-8 · Cited by 26 · see citing works
Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the “Prime Time” of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?
Yang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26 · see citing works
Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice
Zhao, Z., Deng, X., Jia, J., Zhao, L., Wang, C., Cai, Z., Guo, C. Y., Yang, L., Wang, D., Ma, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154921 · Cited by 26 · see citing works
Angiopoietin-like proteins in atherosclerosis
Liu, Y., Zhang, C., Jiang, J.-F., Cheng, Z.-B., Zhou, Z., Tang, M.-Y., Sun, J.-X., & Huang, L. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.06.024 · Cited by 25 · see citing works
Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
Sun, T., Zhan, W., Wei, L., Xu, Z., Li, F., Yang, Z., Wang, C., & Zhang, J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01580-z · Cited by 25 · see citing works
Food-Borne Exposure of Juvenile Rainbow Trout (Oncorhynchus mykiss) to Benzotriazole Ultraviolet Stabilizers Alone and in Mixture Induces Specific Transcriptional Changes
Giraudo, M., Colson, T. L., Silva, A. O. D., Lu, Z., Gagnon, P., Brown, L. L., & Houde, M. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4676 · Cited by 25 · see citing works
The Lipid-Modulating Effect of Tangeretin on the Inhibition of Angiopoietin-like 3 (ANGPTL3) Gene Expression through Regulation of LXRα Activation in Hepatic Cells
Chen, P., Chao, T.-Y., Hsu, H., Wang, C., Lin, C.-Y., Gao, W.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189853 · Cited by 25 · see citing works
Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice
Xiao, H., Liang, L., Luo, Z.-F., & Sun, Z. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.006 · Cited by 24 · see citing works
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25 · see citing works
Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 23 · see citing works
A hepatokine derived from the ER protein CREBH promotes triglyceride metabolism by stimulating lipoprotein lipase activity
Kim, H., Song, Z., Zhang, R., Davies, B. S. J., & Zhang, K. (2023) · Science Signaling · doi:10.1126/scisignal.add6702 · Cited by 23 · see citing works
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23 · see citing works
The interplay between the muscle and liver in the regulation of glucolipid metabolism
Cheng, C., Xie, L., Zhang, M., Shama, S., Cheng, K. K. Y., & Jia, W. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad073 · Cited by 23 · see citing works
Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Mihăilă, R. G. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x15666190522100041 · Cited by 23 · see citing works
Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8
Oldoni, F., Bass, K., Kozlitina, J., Hudson, H., Shihanian, L. M., Gusarova, V., Cohen, J. C., & Hobbs, H. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab120 · Cited by 20 · see citing works
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21 · see citing works
Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
Lu, X. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190621120523 · Cited by 22 · see citing works
Role of GALNT2 on Insulin Sensitivity, Lipid Metabolism and Fat Homeostasis
Antonucci, A., Marucci, A., Trischitta, V., & Paola, R. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020929 · Cited by 22 · see citing works
Sex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats
Dong, Q., Kuefner, M., Deng, X., Bridges, D., Park, E. A., Elam, M. B., & Raghow, R. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0202-x · Cited by 20 · see citing works
Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi
Butler, A. A., Graham, J. L., Stanhope, K. L., Wong, S. C., King, S. M., Bremer, A. A., Krauss, R. M., Hamilton, J., & Havel, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000423 · Cited by 20 · see citing works
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 22 · see citing works
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 21 · see citing works
Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins
DeForest, N., Kavitha, B., Hu, S., Isaac, R., Krohn, L., Wang, M., Du, X., De Arruda Saldanha, C., Gylys, J., Merli, E., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100339 · Cited by 21 · see citing works
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Jin, M., Meng, F., Yang, W., Liang, L., Wang, H., & Zhenyan, F. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001073 · Cited by 21 · see citing works
The endocrine role of hepatokines: implications for human health and disease
Iglesias, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663353 · Cited by 22 · see citing works
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 19 · see citing works
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20 · see citing works
Unexpected omega-3 activities in intracellular lipolysis and macrophage foaming revealed by fluorescence lifetime imaging
Tang, H., Liu, Z., Han, G., Geng, J., Liu, B., Zhang, R., & Zhang, Z. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321255121 · Cited by 19 · see citing works
Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
Wang, J., Zheng, W., Zheng, S., Yuan, Y., Wen, W., Cui, W., Xue, L., Sun, X., Shang, H., Zhang, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.023 · Cited by 18 · see citing works
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
Chan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 18 · see citing works
Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia
Cruz‐Bautista, I., Huerta‐Chagoya, A., Moreno-Macías, H., Rodríguez-Guillén, R., Ordóñez-Sánchez, M. L., Segura-Kato, Y., Mehta, R., Almeda‐Valdés, P., Gómez-Munguía, L., Chávez, X. R.-D., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01436-6 · Cited by 18 · see citing works
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18 · see citing works
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 18 · see citing works
ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome
Zhong, F., Liu, S., Li, Y., Li, G., Liu, M., Wang, J., Cui, W., Suo, Y., & Gao, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01632-y · Cited by 18 · see citing works
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen, R. F., Hovingh, G. K., & Stroes, E. S. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000898 · Cited by 17 · see citing works
Evaluation of rs1748195 ANGPTL3 gene polymorphism in patients with angiographic coronary artery disease compared to healthy individuals
Afkhami, N., Aghasizadeh, M., Hafezi, S. G., Zare‐Feyzabadi, R., Soflaei, S. S., Rashidmayvan, M., Rastegarmoghadam-Ebrahimian, A., Khanizadeh, K., Safari, N., Ferns, G. A., et al. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2105 · Cited by 15 · see citing works
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 15 · see citing works
The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models
Lin, C.-Y., Chen, P., Hsu, H., Gao, W.-Y., Wu, M., & Yen, J.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012485 · Cited by 14 · see citing works
Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14 · see citing works
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis
Ji, B., Liu, J., Yin, Y., Xu, H. M., Shen, Q., & Yu, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06124-0 · Cited by 13 · see citing works
Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14 · see citing works
ANGPTL3 negatively regulates IL-1β-induced NF-κB activation by inhibiting the IL1R1-associated signaling complex assembly
Zhang, Y., Zhang, Z.-T., Wan, S.-Y., Yang, J. X., Wei, Y., Chen, H., Zhou, W.-Z., Song, Q., Niu, S., Zheng, L., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad053 · Cited by 13 · see citing works
Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: Relationship with Vasodilator Dysfunction
Schinzari, F., Vizioli, G., Campia, U., Tesauro, M., & Cardillo, C. (2021) · Biomedicines · doi:10.3390/biomedicines9081037 · Cited by 13 · see citing works

Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Chen, P., Gao, W.-Y., Liou, J.-W., Lin, C.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147310 · Cited by 80 · see citing works
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3 · see citing works
The role of ANGPTL3 in controlling lipoprotein metabolism
Tikka, A., & Jauhiainen, M. (2016) · Endocrine · doi:10.1007/s12020-015-0838-9 · Cited by 131 · see citing works
New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases
Su, X., & Peng, D. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0659-y · Cited by 45 · see citing works
ANGPLT3: A novel modulator of lipid metabolism
Hassan, M. S. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.6 · Cited by 24 · see citing works

Authors: Kersten, S.
Affiliations: Wageningen University & Research (NL)
Corresponding author: Kersten, Sander
ORCID: Kersten, Sander
Venue: Nature Reviews Endocrinology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-06
Volume: 13
Issue: 12
Pages: 731-739
ISSN: 1759-5029 (ISSN-L)
1759-5037
DOI: 10.1038/nrendo.2017.119
OpenAlex: W2761312904
Semantic Scholar: de449b0f2ed915d896023302b106994d388fefb6
Cited by: 220
References: 80
Citations by year: 2026: 23 · 2025: 30 · 2024: 20 · 2023: 22 · 2022: 27 · 2021: 47 · 2020: 25 · 2019: 13 · 2018: 12 · 2017: 1
FWCI: 1.98
Type: journal article
Language: en
Open access: green
research.wur.nl
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Endocrinology (publishedVersion)
PubMed (publishedVersion)
Socio-Environmental Systems Modeling (acceptedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Fondation Leducq
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords: ANGPTL3, angiopoietin-like proteins, lipoprotein lipase inhibition, lipoprotein metabolism, hepatokines, atherosclerosis, loss-of-function mutations, coronary artery disease, dyslipidemia, antisense oligonucleotides, monoclonal antibodies, triglycerides, free fatty acids, ANGPTL4, ANGPTL8
MeSH terms: Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Animals, Antibodies, Monoclonal, Fasting, Fatty Acids, Nonesterified, Food, Humans, Lipoprotein Lipase, Lipoproteins, Liver, Mutation, Triglycerides, Oligonucleotides, Antisense, Dyslipidemias, Atherosclerosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiopoietin-like 3 in lipoprotein metabolism

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks